OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings

Benzinga02-17

OS Therapies on Tuesday said it expects to complete conditional Marketing Authorization Application (MAA) submissions to both the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612450057?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/17/Various-Pharmaceuticals-Pills-Capsules-T.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2026-02-17 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612450057","market":"sh","top_or_hot":-1,"title":"OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings","media":"Benzinga","content":"<div>\n<p>OS Therapies on Tuesday said it expects to complete conditional Marketing Authorization Application (MAA) submissions to both the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) and ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50649664/os-therapies-discloses-2026-timeline-for-lead-drug-regulatory-filings\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-17 22:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/02/50649664/os-therapies-discloses-2026-timeline-for-lead-drug-regulatory-filings><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>OS Therapies on Tuesday said it expects to complete conditional Marketing Authorization Application (MAA) submissions to both the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) and ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50649664/os-therapies-discloses-2026-timeline-for-lead-drug-regulatory-filings\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EMA","symbol_name":"Emera Inc.","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/02/50649664/os-therapies-discloses-2026-timeline-for-lead-drug-regulatory-filings","article_id":"2612450057","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/17/Various-Pharmaceuticals-Pills-Capsules-T.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/02/50649664/os-therapies-discloses-2026-timeline-for-lead-drug-regulatory-filings","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612450057","pubTimestamp":1771336860,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"OS Therapies shares climb after new regulatory plans for OST-HER2 osteosarcoma treatment in the UK, EU, and U.S.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"EMA":"Emera Inc.","BK4588":"碎股","MAA":"MAA房产信托","BK4585":"ETF&股票定投概念","BK4081":"电力公用事业","SMA":"Smartstop Self Storage REIT Inc","BK4139":"生物科技","OSTX":"OS Therapies","BK4215":"住宅房地产投资信托","BK4217":"自存仓储房地产信托"},"translate_title":"OS Therapies披露2026年主要药物监管备案时间表","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSTX":1.5,"MAA":1,"EMA":1,"SMA":1},"content_text":"OS Therapies on Tuesday said it expects to complete conditional Marketing Authorization Application (MAA) submissions to both the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) by the end of the first quarter of 2026.\nAdditionally, the company is on track to submit the Clinical BLA module to the FDA following a Type D meeting anticipated in March 2026.\nThe company is also preparing to release additional biomarker data from its Human Metastatic Osteosarcoma Program in the first quarter of 2026, which aims to further characterize immune pathway activation and evaluate the relationship between biomarker expression and clinical outcomes.\nThis data is expected to support the use of these biomarkers as surrogate endpoints for clinical efficacy.\nAdditionally, the company was informed that Ayala Pharmaceuticals is dissolving.\nThe company acquired all listeria-based clinical, preclinical, and intellectual property assets from Ayala in April 2025, issuing to Ayala the equivalent of 4.8 million shares of OS Therapies common stock.\nAyala completed the liquidation of its OS Therapies shares and no longer holds any securities in the company.\nThe stock is currently trading 8.0% below its 20-day simple moving average (SMA) and 15.0% below its 100-day SMA, indicating some short-term weakness. Over the past 12 months, shares have decreased by 38.07%, and they are currently positioned closer to their 52-week lows than highs, reflecting ongoing challenges for the company.\nThe RSI is at a neutral level, suggesting that the stock is neither overbought nor oversold at this time. Meanwhile, MACD is also neutral, indicating a lack of strong directional momentum for the stock.\nThe combination of neutral RSI and MACD suggests mixed momentum, indicating that traders should be cautious as the stock navigates its current price levels.\nThe stock carries a Buy Rating with an average price target of $18.25. Recent analyst moves include:\nOSTX Price Action: OS Therapies shares were up 2.46% at $1.25 during premarket trading on Tuesday, according to Benzinga Pro data.\nPhoto by Aria Armoko via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612450057","isCrawlerRequest":true}